Phase
Condition
Peripheral Neuropathy
Treatment
Actimyo
Clinical Study ID
Ages 18-99 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Diagnosed with CIDP or possible CIDP based on 2021 EAN/PNS criteria2.
Treated with IVIg (≤1g/kg/3-8week)
Clinically Stable disease for 3 months (according to treating physician opinion).
No treatment withdrawal failure within 1 year
Age over 18 years
Exclusion
Exclusion Criteria:
Significant cognitive or communication disorders
Surgery or serious traumatic injury ≤ 6 months
Non ambulant patient
Current participation to a therapeutic trial
Anti-myeline antibodies (anti-MAG) positive or nodo-paranodopathy
Other autoimmune disease that requires Corticosteroids, IVIg, Plasma Exchangetreatment
Pregnancy or breastfeeding
Any other condition that, according to the investigator, could significantlyinterfere with patient evaluation or safety.
Study Design
Study Description
Connect with a study center
CHR Citadelle
Liège, 4000
BelgiumActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.